Back to search

Article

Albumin Paclitaxel Plus Platinum With or Without Pembrolizumab for Metastatic Primary Pulmonary Lymphoepithelioma-like Carcinoma: a Retrospective Multicenter Study

2021-10-21

Abstract excerpt

<h4>Objectives: </h4> Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is a rare subtype of primary non-small cell lung cancer (NSCLC), and the first-line therapy for metastatic PPLELC patients remains controversial. The purpose of this study was to investigate the efficacy and safety of immune checkpoint inhibitors(ICIs) combined with chemotherapy(CT) compared with traditional chemotherapy in these pat...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
19bc82d4-848d-58b4-b41e-6f606102ffb9
DOI
10.21203/rs.3.rs-966201/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Albumin Paclitaxel Plus Platinum With or Without Pembrolizumab for Metastatic Primary Pulmonary Lymphoepithelioma-like Carcinoma: a Retrospective Multicenter StudyDOI 10.21203/rs.3.rs-966201/v1
Immune Checkpoint Inhibitor without Pemetrexed for First-line Maintenance Therapy in Advanced Lung Adenocarcinoma: A real-world retrospective studySemantic proximity
Comparison of efficacy and safety between PD-1 inhibitors and PD- L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysisSemantic proximity
Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure.Semantic proximity
Pembrolizumab plus bevacizumab achieves long-term progression free survival in patients with lung adenocarcinoma with brain metastases: a case report and literature reviewSemantic proximity
Comprehensive clinicopathological and prognostic analysis of primary pulmonary lymphoepithelial carcinoma: a retrospective cohort study.Semantic proximity
First-line treatment for driver gene–negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab？Semantic proximity
Efficacy and Safety of Immuno-based Therapy Versus Standard of Care in Extensive-stage Small-Cell Lung Cancer: An Updated Meta-analysis of Randomized Clinical TrialsSemantic proximity
Optimal treatment strategies for EGFR mutant advanced lung adenocarcinoma patients with targeted therapy resistance and correlation analysis of PD-L1 expression with ICI efficacy.Semantic proximity
Breaking Down Combination Strategies: PD-1/PD-L1 Inhibitors with Chemotherapy, Anti- Angiogenesis, or Both in Driver Gene-Negative NSCLC Clinical Outcomes and Mechanistic InsightsSemantic proximity
Optimal Treatment Strategies for EGFR Mutant Advanced Lung Adenocarcinoma Patients with Targeted Therapy Resistance and Correlation Analysis of PD-L1 Expression with ICI EfficacySemantic proximity
Efficacy and safety of different PD-1 inhibitors as first-line treatment for advanced or metastatic squamous non-small cell lung cancer: A retrospective real-world studySemantic proximity
Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung CancerSemantic proximity
Select a neighboring publication to make it the new centre.